Mundipharma
Liu Yang PhD currently serves as the Technical Programme Management Manager at Mundipharma, a position held since March 2022. Prior experience includes leading roles at Purdue Pharma (Canada) from June 2012 to March 2022, where achievements encompassed heading the Pharmaceutics & Analytics department and managing Pharmaceutical R&D. Liu Yang's career began at Covalon Technologies Inc. as a Scientist/Project Leader, focusing on controlled release systems and biomolecular applications, and includes a postdoctoral fellowship at Mount Sinai Hospital, Toronto, specializing in tissue engineering and biomaterials. Liu Yang earned a Ph.D. in Biomedical Engineering from the University of Toronto, developing expertise in polymer science, tissue engineering, and regulatory submissions.
This person is not in any teams
This person is not in any offices
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.